Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating escalating doses of the investigational agent BMS-986463 to assess safety, tolerability, and early signals of activity in adults with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Carcinoma
• Non-small Cell Lung Cancer
• Uterine Serous Carcinoma

Drugs mentioned

• BMS-986463

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC) | Phase 1 | Status: RECRUITING